Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02261220 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 380
- Enrollment target
NCT02261220 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 380 participants.
The verdict
NCT02261220, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 380 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.
Interventions
- BIOLOGICAL MEDI4736
- BIOLOGICAL tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2014-10-13 |
| Est. Completion | 2020-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02261220
The ClinicalTrials.gov registry entry for NCT02261220 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI4736 is the first listed.
NCT02261220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02261220 about?
NCT02261220 is a clinical study titled "A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors". This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.
What is the current status of trial NCT02261220?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 380 participants. The study started on 2014-10-13. Estimated completion is 2020-01-27.
What interventions are being tested in trial NCT02261220?
The interventions under investigation include: MEDI4736 (BIOLOGICAL), tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02261220?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.